DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。医学上迫切需要一种预防性的丙型肝炎疫苗。全球普遍存在丙型肝炎病毒感染，这是非肠道接触该病毒的结果。在发达国家，最常见的风险因素是静脉注射吸毒者共用针头。其他高危人群包括阳性母亲所生的婴儿、有频繁和多个异性伴侣的个人、卫生保健工作者、有受感染家庭成员的个人和血液透析患者。美国疾病控制与预防中心估计，每年大约有30,000名新感染者。在发展中国家，同样的风险因素是显而易见的，但此外，非无菌医疗注射做法极大地造成了目前的疾病负担，这是可悲的。涉及非肠道接触病毒的文化习俗也被认为在发展中国家的传播中发挥着重要作用。因此，迫切需要开发一种预防性疫苗。我们打算用异源丙型肝炎病毒株来测试对抗延迟挑战的有效性。几种候选疫苗将在5只黑猩猩身上进行测试，以激发对丙型肝炎病毒的体液和细胞免疫反应。显著的免疫原性的证明将导致对异源1a型丙型肝炎病毒株疫苗的挑战。这项研究正在进行中。结果将是专有的。未来的方向将由商业SPO决定

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is an urgent medical need for a preventive HCV vaccine. HCV infection occurs commonly around the globe as a result of parenteral exposure to the virus. In developed countries, the most common risk factor is sharing of needles amongst iv drug users. Other ¿at-risk¿ groups include babies born to positive mothers, individuals with frequent and multiple heterosexual partners, health-care workers, individuals with an infected family member, and hemodialysis patients. In the USA, the CDC has estimated that there are roughly 30,000 new infections annually. In developing countries, the same risk factors are evident but in addition, non-sterile medical injection practices have contributed hugely and tragically to the current disease burden. Cultural practices involving parenteral exposure to the virus are also thought to play an important role in transmission in the developing world. Therefore, there is an urgent need for the development of a prophylactic vaccine. We intend to test efficacy against a delayed challenge with a heterologous HCV strain. Several candidate vaccines will be tested in groups of 5 chimpanzees for the elicitation of humoral and cellular immune responses to HCV. The demonstration of significant immunogenicity will then lead to challenge of vaccines with a heterologous 1a HCV strain. This study is in progress. Results will be proprietary. Future directions will be determined by the commercial spo